Biora Therapeutics (NASDAQ:BIOR) Price Target Raised to $23.00

Biora Therapeutics (NASDAQ:BIOR) had its price objective boosted by HC Wainwright from $15.00 to $23.00 in a report published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Biora Therapeutics Stock Performance

Shares of NASDAQ:BIOR opened at $1.62 on Monday. Biora Therapeutics has a 52-week low of $1.43 and a 52-week high of $19.90. The firm has a market capitalization of $7.33 million, a P/E ratio of -0.13 and a beta of 1.27. The stock has a 50 day moving average price of $4.54 and a 200-day moving average price of $5.96.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.